These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 29904848)

  • 41. Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study.
    Blumenfeld AM; Stark RJ; Freeman MC; Orejudos A; Manack Adams A
    J Headache Pain; 2018 Feb; 19(1):13. PubMed ID: 29404713
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Botulinum toxin type A for preventive treatment of chronic migraines].
    Göbel H; Heinze A
    HNO; 2012 Jun; 60(6):490-5. PubMed ID: 22669437
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Botox, migraine, and the American Academy of Neurology: an antidote to anecdote.
    Jackson M; Barbuto JP
    J Manag Care Pharm; 2008 Jun; 14(5):465-7. PubMed ID: 18597576
    [No Abstract]   [Full Text] [Related]  

  • 44. Effect of OnabotulinumtoxinA Injection on Depression in Chronic Migraine.
    Maasumi K; Thompson NR; Kriegler JS; Tepper SJ
    Headache; 2015 Oct; 55(9):1218-24. PubMed ID: 26381856
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Botulinum toxin type A: myths, facts, and current research.
    Silberstein SD; Aoki KR
    Headache; 2003; 43 Suppl 1():S1. PubMed ID: 12887387
    [No Abstract]   [Full Text] [Related]  

  • 46. May migraine attack response to triptans be a predictor of the efficacy of Onabotulinum toxin-A prophylaxis?
    Lovati C; Giani L; Mariotti D Alessandro C; Tabaee Damavandi P; Mariani C; Pantoni L
    Neurol Sci; 2018 Jun; 39(Suppl 1):153-154. PubMed ID: 29904874
    [No Abstract]   [Full Text] [Related]  

  • 47. Licence for Botox in so-called chronic migraine.
    Olesen J; Tfelt-Hansen P
    Lancet; 2010 Nov; 376(9755):1825-6; discussion 1826. PubMed ID: 21111904
    [No Abstract]   [Full Text] [Related]  

  • 48. Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data.
    Davies B; Gaul C; Martelletti P; García-Moncó JC; Brown S
    J Headache Pain; 2017 Sep; 18(1):93. PubMed ID: 28879545
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Botulinum toxin type a for chronic migraine.
    Ashkenazi A
    Curr Neurol Neurosci Rep; 2010 Mar; 10(2):140-6. PubMed ID: 20425239
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Botulinum toxin for chronic migraine.
    Med Lett Drugs Ther; 2011 Jan; 53(1356):7-8. PubMed ID: 21252842
    [No Abstract]   [Full Text] [Related]  

  • 51. Iron Deposits in Periaqueductal Gray Matter Are Associated with Poor Response to OnabotulinumtoxinA in Chronic Migraine.
    Domínguez Vivero C; Leira Y; Saavedra Piñeiro M; Rodríguez-Osorio X; Ramos-Cabrer P; Villalba Martín C; Sobrino T; Campos F; Castillo J; Leira R
    Toxins (Basel); 2020 Jul; 12(8):. PubMed ID: 32731573
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of Botulinum Toxin A on Allodynia in Chronic Migraine: An Observational Open-Label Two-Year Study.
    de Tommaso M; Brighina F; Delussi M
    Eur Neurol; 2019; 81(1-2):37-46. PubMed ID: 31013496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.
    Kollewe K; Escher CM; Wulff DU; Fathi D; Paracka L; Mohammadi B; Karst M; Dressler D
    J Neural Transm (Vienna); 2016 May; 123(5):533-40. PubMed ID: 27032774
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Botulinum toxin: A lift for chronic migraines.
    Sanassi LA
    JAAPA; 2016 Jun; 29(6):1-4. PubMed ID: 27228039
    [TBL] [Abstract][Full Text] [Related]  

  • 55. CGRP and PTX3 as Predictors of Efficacy of Onabotulinumtoxin Type A in Chronic Migraine: An Observational Study.
    Domínguez C; Vieites-Prado A; Pérez-Mato M; Sobrino T; Rodríguez-Osorio X; López A; Campos F; Martínez F; Castillo J; Leira R
    Headache; 2018 Jan; 58(1):78-87. PubMed ID: 29131327
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CGRP and VIP levels as predictors of efficacy of Onabotulinumtoxin type A in chronic migraine.
    Cernuda-Morollón E; Martínez-Camblor P; Ramón C; Larrosa D; Serrano-Pertierra E; Pascual J
    Headache; 2014 Jun; 54(6):987-95. PubMed ID: 24673487
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report.
    Bohluli B; Motamedi MH; Bagheri SC; Bayat M; Lassemi E; Navi F; Moharamnejad N
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2011 Jan; 111(1):47-50. PubMed ID: 20674409
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Botox for migraines?
    Harv Health Lett; 2010 Apr; 35(6):7. PubMed ID: 20513148
    [No Abstract]   [Full Text] [Related]  

  • 59. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
    Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
    Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
    [TBL] [Abstract][Full Text] [Related]  

  • 60. OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.
    Domínguez C; Pozo-Rosich P; Torres-Ferrús M; Hernández-Beltrán N; Jurado-Cobo C; González-Oria C; Santos S; Monzón MJ; Latorre G; Álvaro LC; Gago A; Gallego M; Medrano V; Huerta M; García-Alhama J; Belvís R; Leira Y; Leira R
    Eur J Neurol; 2018 Feb; 25(2):411-416. PubMed ID: 29171146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.